Mutant and wild-type Ras: co-conspirators in cancer
Open accessAbstract
Summary: Although the functional interplay between mutant and wild-type Ras in driving tumor initiation and growth has been described, a clear picture of the precise ramifications and mechanisms of this association remains elusive, sometimes with conflicting conclusions. A report in this issue of Cancer Discovery tackles this question, which may have important implications for therapeutic strategies to block mutant Ras for cancer treatment. Cancer Discov; 3(1); 24–6. ©2012 AACR. See related article by Young et al., p. 112
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combining a mutant-specific KRAS inhibitor with a SHP2 or SOS1 inhibitor could block both mutant KRAS and wild-type RAS signaling.
“A combination of a mutant specific KRAS inhibitor with either a SHP2 inhibitor or a SOS1 inhibitor could effectively block mutant KRAS and wild-type RAS signaling (12, 43, 45, 46).”
From Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants (2022) · cites this paper as [46]
In heterozygous KRAS mutant tumor cells, RAS signaling can be supplemented and cross-regulated by RTK-WT RAS signaling.
“In heterozygous KRAS mutant tumor cells, RAS signaling can be supplemented and cross-regulated by RTK-WT RAS signaling.”
From Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants (2022) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Inhibition of NIH 3T3 Cell Proliferation by a Mutant ras Protein with Preferential Affinity for GDP
Feig, L. A., & Cooper, G. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.8.3235-3243.1988 · Cited by 799 · see citing works
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706 · see citing works
Self-citationMaurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618 · see citing works
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · see citing works
Tumour maintenance is mediated by eNOS
Lim, K., Ancrile, B. B., Kashatus, D. F., & Counter, C. M. (2008) · Nature · doi:10.1038/nature06778 · Cited by 315 · see citing works
Wildtype Kras2 can inhibit lung carcinogenesis in mice
Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L. T., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 295 · see citing works
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211 · see citing works
Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
Jeng, H., Taylor, L. J., & Bar‐Sagi, D. (2012) · Nature Communications · doi:10.1038/ncomms2173 · Cited by 176 · see citing works
Quilliam, L. A., Kato, K., Rabun, K. M., Hisaka, M. M., Huff, S. Y., Campbell, S. L., & Der, C. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1113 · Cited by 90 · see citing works
Self-citation
Flagged first, then by citations
2 of the 11 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Expanding the Reach of Precision Oncology by Drugging All <i>KRAS</i> Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336 · see citing works
Small-molecule modulation of Ras signaling
Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N., & Waldmann, H. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1560 · Cited by 215 · see citing works
Shin, S., Choi, D.-K., Jung, K., Bae, J., Kim, J., Park, S.-W., Song, K.-H., & Kim, Y. (2017) · Nature Communications · doi:10.1038/ncomms15090 · Cited by 144 · see citing works
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 146 · see citing works
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75 · see citing works
Chen, X., Makarewicz, J., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2013) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 46 · see citing works
Kim, E., Kim, J., Smith, M. A., Haura, E. B., & Anderson, A. R. A. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002930 · Cited by 44 · see citing works
An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
Shankar, S., Tien, J. C.-Y., Siebenaler, R. F., Chugh, S., Dommeti, V. L., Zelenka-Wang, S., Waninger, J. J., Juckette, K. M., Xu, A., Wang, X.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16309-2 · Cited by 46 · see citing works
Kim, H., Lin, D., Lee, H., Li, M., & Liebler, D. C. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o115.056713 · Cited by 44 · see citing works
Ariës, I. M., van den Dungen, R., Koudijs, M. J., Cuppen, E. P. J. G., Voest, E. E., Molenaar, J. J., Caron, H. N., Pieters, R., & den Boer, M. L. (2014) · Haematologica · doi:10.3324/haematol.2014.112995 · Cited by 40 · see citing works
Chen, F., Wang, X., Fu, S., Wang, S., Fu, Y., Liu, Z., & Zhang, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s259393 · Cited by 24 · see citing works
SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers
Schuld, N. J., Hauser, A. D., Gastonguay, A. J., Wilson, J. M., Lorimer, E., & Williams, C. L. (2014) · Cell Cycle · doi:10.4161/cc.27804 · Cited by 21 · see citing works
The Role of the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Cancer
Lotfaliansaremi, S., Sabio, M. L., Comwell, S., & Tolias, P. P. (2020) · Medical Research Archives · doi:10.18103/mra.v8i4.2086 · Cited by 3 · see citing works
- Authors
- Hayes, T. K., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Der, Channing J.
- Venue
- Cancer Discovery
- Published
- 2013-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 24-26
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC3808242
- OpenAlex
- W2154115960
- Cited by
- 13
- References
- 11
- Citations by year
- 2022: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 2 · 2014: 3 · 2013: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (T32CA071341)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS wild-type, tumor initiation, tumor growth, oncogenic signaling
- MeSH terms
- Humans, Neoplasms, Genes, ras, Mitogen-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
